Craig Gedye
@craiggedye.bsky.social
Medical oncologist, physician/scientist
#cansky #oncosky #clinicaltrials #kidneycancer #braincancer #prostatecancer #btsm #pcsm #kcsm @anzuptrials.bsky.social @COGNOtrials @iconcancercentre.bsky.social
Posts my opinion only. #FCOI http://bit.ly/3xKTdPm
#cansky #oncosky #clinicaltrials #kidneycancer #braincancer #prostatecancer #btsm #pcsm #kcsm @anzuptrials.bsky.social @COGNOtrials @iconcancercentre.bsky.social
Posts my opinion only. #FCOI http://bit.ly/3xKTdPm
Pinned
Craig Gedye
@craiggedye.bsky.social
· Nov 17
A starter pack for people living, working, treating, studying kidney cancer #kidneycancer #kcsm #renalcellcarcinoma #RCC, please share and suggest
go.bsky.app/JGYhGhd
go.bsky.app/JGYhGhd
When life gives you sour mandarins...
October 19, 2025 at 9:56 PM
When life gives you sour mandarins...
Thanks so much to @anzuptrials.bsky.social for helping us starting putting the NZ into ANZUP - great ideas shared on the day for clinical trials for people with GU and prostate cancers in NZ and maybe also AUS as well!
First @anzuptrials.bsky.social Ideas Generation Workshop in New Zealand - putting the NZ into ANZUP! Thanks to Nicky Lawrence and @craiggedye.bsky.social for the warm welcome.
September 16, 2025 at 9:23 PM
Thanks so much to @anzuptrials.bsky.social for helping us starting putting the NZ into ANZUP - great ideas shared on the day for clinical trials for people with GU and prostate cancers in NZ and maybe also AUS as well!
Fantastic to have this critical advice for older people with cancer - thank you @crisbergerot.bsky.social @bogda-koczwara.bsky.social and team
🚨New @ascocancer.bsky.social Guideline Alert! 🌍
Honored to have worked alongside #EnriqueSoto & cols in developing this guideline
Check out the latest recommendations on GA, designed to improve care worldwide
📄Full guideline ascopubs.org/doi/pdf/10.1...
🎙️Don’t miss the accompanying podcast!
Honored to have worked alongside #EnriqueSoto & cols in developing this guideline
Check out the latest recommendations on GA, designed to improve care worldwide
📄Full guideline ascopubs.org/doi/pdf/10.1...
🎙️Don’t miss the accompanying podcast!
September 4, 2025 at 9:14 PM
Fantastic to have this critical advice for older people with cancer - thank you @crisbergerot.bsky.social @bogda-koczwara.bsky.social and team
Reposted by Craig Gedye
Online today! *Aging, Immune Fitness and Cancer* 🔬 Learn the latest about the intersection between these processes in
@natrevcancer.nature.com 🧬 Great to work with
@sandramcallister.bsky.social lab again 😁 doi.org/10.1038/s415...
@natrevcancer.nature.com 🧬 Great to work with
@sandramcallister.bsky.social lab again 😁 doi.org/10.1038/s415...
August 15, 2025 at 2:57 PM
Online today! *Aging, Immune Fitness and Cancer* 🔬 Learn the latest about the intersection between these processes in
@natrevcancer.nature.com 🧬 Great to work with
@sandramcallister.bsky.social lab again 😁 doi.org/10.1038/s415...
@natrevcancer.nature.com 🧬 Great to work with
@sandramcallister.bsky.social lab again 😁 doi.org/10.1038/s415...
One more of my votes for the #Hottest100 #TripleJ in the #Hottest200 today... The Whitlams - Blow Up The Pokies www.youtube.com/watch?v=7B49..., still as relevant today www.theguardian.com/australia-ne...
The Whitlams - Blow Up The Pokies (Official Video)
YouTube video by thewhitlamsofficial
www.youtube.com
August 2, 2025 at 8:41 AM
One more of my votes for the #Hottest100 #TripleJ in the #Hottest200 today... The Whitlams - Blow Up The Pokies www.youtube.com/watch?v=7B49..., still as relevant today www.theguardian.com/australia-ne...
Question remains, is the abscopal effect real? Or is #RT just additive? Certainly evidence for modifying TME, intriguing data for WNT-mt patients when adding #radiotherapy to #PD1 #immunotherapy, but the idea of #RT being a 'vaccine', expanding the immune repertoire, is shown in just 1-2 patients.
🚨ARTICLE now published at Nature Cancer !
✏️By Valsamo Anagnostou and colleagues
'Combination of pembrolizumab and radiotherapy induces systemic antitumor immune responses in immunologically cold non-small cell lung cancer'
🔗 www.nature.com/articles/s43...
✏️By Valsamo Anagnostou and colleagues
'Combination of pembrolizumab and radiotherapy induces systemic antitumor immune responses in immunologically cold non-small cell lung cancer'
🔗 www.nature.com/articles/s43...
Combination of pembrolizumab and radiotherapy induces systemic antitumor immune responses in immunologically cold non-small cell lung cancer - Nature Cancer
Huang et al. analyzed serial samples from participants with metastatic non-small cell lung cancer treated with radiotherapy followed by immunotherapy and report improved clinical outcomes and enhanced...
www.nature.com
July 30, 2025 at 9:24 PM
Question remains, is the abscopal effect real? Or is #RT just additive? Certainly evidence for modifying TME, intriguing data for WNT-mt patients when adding #radiotherapy to #PD1 #immunotherapy, but the idea of #RT being a 'vaccine', expanding the immune repertoire, is shown in just 1-2 patients.
Reposted by Craig Gedye
The Renal IGW is fast approaching. Concept submissions close in 1 week!
Register your attendance here anzup.org.au/idea-generat...
@craiggedye.bsky.social
Register your attendance here anzup.org.au/idea-generat...
@craiggedye.bsky.social
July 28, 2025 at 3:00 AM
The Renal IGW is fast approaching. Concept submissions close in 1 week!
Register your attendance here anzup.org.au/idea-generat...
@craiggedye.bsky.social
Register your attendance here anzup.org.au/idea-generat...
@craiggedye.bsky.social
Reposted by Craig Gedye
Two opinions that to my surprise are either unpopular or not widely held:
1. The control arm of a randomised trial should be best standard of care.
2. A PFS benefit against an inactive comparator is not a major advance, if progressive disease is required for eligibility.
1. The control arm of a randomised trial should be best standard of care.
2. A PFS benefit against an inactive comparator is not a major advance, if progressive disease is required for eligibility.
July 26, 2025 at 10:40 PM
Two opinions that to my surprise are either unpopular or not widely held:
1. The control arm of a randomised trial should be best standard of care.
2. A PFS benefit against an inactive comparator is not a major advance, if progressive disease is required for eligibility.
1. The control arm of a randomised trial should be best standard of care.
2. A PFS benefit against an inactive comparator is not a major advance, if progressive disease is required for eligibility.
Reposted by Craig Gedye
Great kickoff to clinical trials workshop #ANZUP25 — #MelissaLeMesurier w patient perspective and #ChrisGianacas biostats on collaborative efforts for clinical trials. Same global themes for clinical trial development. @anzuptrials.bsky.social @craiggedye.bsky.social @profiand.bsky.social
July 19, 2025 at 11:19 PM
Great kickoff to clinical trials workshop #ANZUP25 — #MelissaLeMesurier w patient perspective and #ChrisGianacas biostats on collaborative efforts for clinical trials. Same global themes for clinical trial development. @anzuptrials.bsky.social @craiggedye.bsky.social @profiand.bsky.social
Tremendous insights with immediate patient impact; using genomic data we can collect routinely from today's patients, we may be able to predict upfront resistance, rather than subject people to 3-4 cycles of chemo, and we might also be strategic if we know people have sensitive cancers - bravo!
🚨Chemo treatment upgrade!🚨
Check out our approach to modernise chemotherapy treatment published today in @natgenet.nature.com. From @cniostopcancer.bsky.social #TailorBio @cruk-ci.bsky.social www.nature.com/articles/s41... More details 👇
Check out our approach to modernise chemotherapy treatment published today in @natgenet.nature.com. From @cniostopcancer.bsky.social #TailorBio @cruk-ci.bsky.social www.nature.com/articles/s41... More details 👇
www.nature.com
June 23, 2025 at 9:12 PM
Tremendous insights with immediate patient impact; using genomic data we can collect routinely from today's patients, we may be able to predict upfront resistance, rather than subject people to 3-4 cycles of chemo, and we might also be strategic if we know people have sensitive cancers - bravo!
Reposted by Craig Gedye
Friends, I have news.
It is very good news.
You'll just have to read it, I'm afraid.
jamesclaims.substack.com/p/introducin...
It is very good news.
You'll just have to read it, I'm afraid.
jamesclaims.substack.com/p/introducin...
Introducing the Medical Evidence Project
And the quest to make less dead people
jamesclaims.substack.com
June 4, 2025 at 2:32 AM
Friends, I have news.
It is very good news.
You'll just have to read it, I'm afraid.
jamesclaims.substack.com/p/introducin...
It is very good news.
You'll just have to read it, I'm afraid.
jamesclaims.substack.com/p/introducin...
Reposted by Craig Gedye
Acquired resistance limits the efficacy of cancer treatments & accounts for therapy failure in most patients. Our Roadmap explores how innovative technologies bridge the gap between fundamental research on resistance and clinical translation into actionable strategies
www.nature.com/articles/s41...
www.nature.com/articles/s41...
Acquired resistance in cancer: towards targeted therapeutic strategies - Nature Reviews Cancer
Acquired therapeutic resistance is a key contributor to cancer treatment failure, requiring new approaches to address its complex mechanisms. In this Roadmap, Soragni, Knudsen and colleagues discuss t...
www.nature.com
June 3, 2025 at 3:35 PM
Acquired resistance limits the efficacy of cancer treatments & accounts for therapy failure in most patients. Our Roadmap explores how innovative technologies bridge the gap between fundamental research on resistance and clinical translation into actionable strategies
www.nature.com/articles/s41...
www.nature.com/articles/s41...
Reposted by Craig Gedye
Meet Cherrie, one of the earliest participants in the CHALLENGE trial, and my colleague Janette Vardy talking about what these results mean.
www.9news.com.au/videos/natio...
www.9news.com.au/videos/natio...
9News - Latest news and headlines from Australia and the world
Latest news and headlines from Australia and the world
www.9news.com.au
June 2, 2025 at 10:28 AM
Meet Cherrie, one of the earliest participants in the CHALLENGE trial, and my colleague Janette Vardy talking about what these results mean.
www.9news.com.au/videos/natio...
www.9news.com.au/videos/natio...
Reposted by Craig Gedye
Presenting at #ASCO25 today!
I was expecting to find evidence that oncologists prefer more-lucrative treatments, and was surprised by our results! Clinical benefit matters, drug profit did not.
Cc @dusetzinas.bsky.social
I was expecting to find evidence that oncologists prefer more-lucrative treatments, and was surprised by our results! Clinical benefit matters, drug profit did not.
Cc @dusetzinas.bsky.social
May 31, 2025 at 9:25 PM
Presenting at #ASCO25 today!
I was expecting to find evidence that oncologists prefer more-lucrative treatments, and was surprised by our results! Clinical benefit matters, drug profit did not.
Cc @dusetzinas.bsky.social
I was expecting to find evidence that oncologists prefer more-lucrative treatments, and was surprised by our results! Clinical benefit matters, drug profit did not.
Cc @dusetzinas.bsky.social
#Teletrials in action: a generous and kind participant called me this week for Visit #3 of his participation in @anzuptrials.bsky.social #ANZadapt #clinicaltrial. “Where are you?”, I asked. “Let me send you a photo”, he said. How’s the serenity…
May 9, 2025 at 9:52 PM
#Teletrials in action: a generous and kind participant called me this week for Visit #3 of his participation in @anzuptrials.bsky.social #ANZadapt #clinicaltrial. “Where are you?”, I asked. “Let me send you a photo”, he said. How’s the serenity…
Reposted by Craig Gedye
🚨 Public consultations now open: help shape how medicine information is shared with patients.
We are reviewing the template used for EU package leaflets. Have your say on how to make them more understandable and relevant to patients.
🔗 Learn more & share your input:
europa.eu/!TCm47q
We are reviewing the template used for EU package leaflets. Have your say on how to make them more understandable and relevant to patients.
🔗 Learn more & share your input:
europa.eu/!TCm47q
April 16, 2025 at 9:23 AM
🚨 Public consultations now open: help shape how medicine information is shared with patients.
We are reviewing the template used for EU package leaflets. Have your say on how to make them more understandable and relevant to patients.
🔗 Learn more & share your input:
europa.eu/!TCm47q
We are reviewing the template used for EU package leaflets. Have your say on how to make them more understandable and relevant to patients.
🔗 Learn more & share your input:
europa.eu/!TCm47q
Reposted by Craig Gedye
Excellent, thought-provoking presentation by Deb Maskens of IKCC on the % of patients that are not being reached by #KidneyCancer organisations and strategies to consider on how we can improve. #IKCC25 @debmaskens.bsky.social
April 6, 2025 at 8:10 PM
Excellent, thought-provoking presentation by Deb Maskens of IKCC on the % of patients that are not being reached by #KidneyCancer organisations and strategies to consider on how we can improve. #IKCC25 @debmaskens.bsky.social
Welcome @myesmo.bsky.social!
🚀 ESMO is now on Bluesky
This is not an April Fools' announcement, nor is it an AI-generated post. ESMO is launching on Bluesky with a poll on AI to start the conversation.
Join us for the latest in oncology education and information.
#AIOncology #HealthAI #ESMOAI25
This is not an April Fools' announcement, nor is it an AI-generated post. ESMO is launching on Bluesky with a poll on AI to start the conversation.
Join us for the latest in oncology education and information.
#AIOncology #HealthAI #ESMOAI25
April 1, 2025 at 9:05 AM
Welcome @myesmo.bsky.social!
Great piece from Lancet Global Health on democratising clinical trials research to strengthen primary healthcare, relevant to ALL healthcare. Every healthcare intervention is a clinical trial of n = 1; why not learn from every patient, every clinician?
March 27, 2025 at 8:44 PM
Great piece from Lancet Global Health on democratising clinical trials research to strengthen primary healthcare, relevant to ALL healthcare. Every healthcare intervention is a clinical trial of n = 1; why not learn from every patient, every clinician?
Reposted by Craig Gedye
Psych. Science just published a paper showing that the "warm glow" of donations can reduce depressive symptoms (d = [0.19, 0.46]).
Most impressively, "micro" donations (one Chinese cent, or $0.0014) appear sufficient to trigger these large effects.
Big if true? Let's dive in.
Most impressively, "micro" donations (one Chinese cent, or $0.0014) appear sufficient to trigger these large effects.
Big if true? Let's dive in.
March 11, 2025 at 6:05 PM
Psych. Science just published a paper showing that the "warm glow" of donations can reduce depressive symptoms (d = [0.19, 0.46]).
Most impressively, "micro" donations (one Chinese cent, or $0.0014) appear sufficient to trigger these large effects.
Big if true? Let's dive in.
Most impressively, "micro" donations (one Chinese cent, or $0.0014) appear sufficient to trigger these large effects.
Big if true? Let's dive in.
Note to anyone writing #clinicaltrial protocols: the word ‘subjects’ is pejorative and rude – people suffering illness may become patients of healthcare services, but transform themselves into participants when they volunteer to take part in clinical trials. Subjects are things we took at school.
March 9, 2025 at 9:22 PM
Note to anyone writing #clinicaltrial protocols: the word ‘subjects’ is pejorative and rude – people suffering illness may become patients of healthcare services, but transform themselves into participants when they volunteer to take part in clinical trials. Subjects are things we took at school.
There was messenger, transfer, ribosomal... then there was micro, then there was long non-coding, then circular, then MySpace, then Tumblr, Insta, Snapchat, TikTok... and then I gave up counting...
February 26, 2025 at 8:29 PM
There was messenger, transfer, ribosomal... then there was micro, then there was long non-coding, then circular, then MySpace, then Tumblr, Insta, Snapchat, TikTok... and then I gave up counting...
Send in the clones. Two papers in this week's @nature.com compare/contrast personalized neoantigen mRNA vaccines, with extraordinary success as adjuvant therapy in pancreatic cancer, but not helping when given late in lung cancer. Targeting ALL clones of each person's cancer is essential.
February 23, 2025 at 8:08 AM
Send in the clones. Two papers in this week's @nature.com compare/contrast personalized neoantigen mRNA vaccines, with extraordinary success as adjuvant therapy in pancreatic cancer, but not helping when given late in lung cancer. Targeting ALL clones of each person's cancer is essential.
Take your chemo at night? Retrospective analysis of two large clinical trials suggests when you take temozolomide (am, pm, night) makes no difference in survival in #glioblastoma. Side effects might be better if taken at night. academic.oup.com/nop/advance-... @eortc.bsky.social
February 22, 2025 at 2:45 AM
Take your chemo at night? Retrospective analysis of two large clinical trials suggests when you take temozolomide (am, pm, night) makes no difference in survival in #glioblastoma. Side effects might be better if taken at night. academic.oup.com/nop/advance-... @eortc.bsky.social
Reposted by Craig Gedye
Progress for chromophobe RCC at ASCO GU. Excited to check out the FOUR abstracts for #chRCC tomorrow (H31, H18, E21, E36) #chromophobe #GU25
@msaouel.bsky.social
@msaouel.bsky.social
February 15, 2025 at 4:49 AM
Progress for chromophobe RCC at ASCO GU. Excited to check out the FOUR abstracts for #chRCC tomorrow (H31, H18, E21, E36) #chromophobe #GU25
@msaouel.bsky.social
@msaouel.bsky.social